Please check your internet connection and try again.
# IV Dexamethasone
## Overview
Dexamethasone is a potent synthetic corticosteroid with anti-inflammatory and immunosuppressive properties.
## Primary Indications
* Allergic states
* Dermatologic diseases
* Endocrine disorders
* Gastrointestinal diseases
* Hematologic disorders
* Neoplastic diseases
* Nervous system disorders
* Ophthalmic diseases
* Renal diseases
* Respiratory diseases
* Rheumatic disorders
* Shock
## Adult Dosing
Dosing is highly variable and depends on the specific indication and severity of the condition.
* **Replacement therapy (e.g., adrenal insufficiency):** 0.5 to 9 mg daily.
* **Anti-inflammatory/immunosuppressive:** 0.5 to 9 mg daily. Higher doses may be used for severe conditions, such as cerebral edema (e.g., 10 mg initial dose, then 4 mg every 6 hours as needed). Doses can range from 4 mg to 24 mg daily or higher.
* **Treatment of COVID-19 in hospitalized patients requiring oxygen:** 6 mg once daily.
Dosage, frequency, and duration are guided by patient response and clinical judgment. Doses may be tapered to discontinue.
## Pediatric Dosing
Dosing is based on severity of condition, not on body weight or surface area, but may be calculated based on weight for certain indications (e.g., 0.15 to 0.3 mg/kg/day divided every 6 to 12 hours). Doses must be individualized.
## Dose Adjustments
* **Hepatic Impairment:** No specific dose adjustment is typically recommended, but monitor closely as metabolism may be altered.
* **Renal Impairment:** No specific dose adjustment is typically recommended.
## Contraindications
* Systemic fungal infections
* Hypersensitivity to dexamethasone or other components of the formulation
## Adverse Effects
Common: hyperglycemia, insomnia, increased appetite, mood changes, fluid retention, electrolyte disturbances (hypokalemia), increased risk of infection, peptic ulceration, impaired wound healing.
Less Common: adrenal suppression, osteoporosis, muscle weakness, Cushingoid appearance, vision changes, pancreatitis, skin rash.
## Key Drug Interactions
* **CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, barbiturates):** May increase dexamethasone clearance, requiring a dose increase.
* **CYP3A4 inhibitors (e.g., ketoconazole, itraconazole):** May decrease dexamethasone clearance, potentially requiring a dose decrease.
* **Diuretics (potassium-depleting):** Increased risk of hypokalemia.
* **Antidiabetic agents:** May decrease efficacy.
* **Warfarin:** May alter anticoagulant effect.
* **Live vaccines:** Increased risk of disseminated infection.
## Monitoring
* Blood glucose levels
* Electrolytes (especially potassium)
* Signs of infection
* Blood pressure
* Growth in pediatric patients
* Signs of adrenal suppression (especially upon withdrawal)
* Bone mineral density (with long-term use)
## Clinical Pearls
* Administer via IV push or infusion.
* May be given intramuscularly, orally, intra-articularly, intralesionally, or topically depending on the formulation and indication.
* Doses should be tapered gradually when discontinuing to avoid adrenal insufficiency.
* Prophylactic measures against opportunistic infections (e.g., PCP prophylaxis) may be considered with prolonged high-dose therapy.
* Corticosteroid use can mask signs of infection.
***
**Disclaimer:** This information is for educational purposes only and does not substitute for professional medical advice. Always consult with a qualified healthcare provider to ensure the most current and accurate information regarding diagnosis and treatment. Verify current prescribing information before making any treatment decisions.
